Alzheimer’s drugs eyed as next big obesity-like opportunity
Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...
The Misconceptions About Anavex Life Sciences' Blarcamesine Phase 2b/3 Trial In Alzheimer's Disease
Anavex Life Sciences' Blarcamesine trial raises concerns over approval. Learn why AVXL stock is undervalued, reflecting the ...
Alzheimer’s Drugs Eyed by Investors Seeking Obesity-Like Gains
Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...
Could Alzheimer’s treatment drugs be the next big investor opportunity after obesity pills?
Alzheimer’s drugs could unlock a $13 billion market by 2030, with Biogen, Eli Lilly, Novo Nordisk, Roche, and UCB leading the ...
studyfinds2d
Finally, an accurate blood test for Alzheimer’s at its earliest stages could be on horizon
Discover a groundbreaking study that may help detect Alzheimer's in its early stages. Learn about the link between blood ...
360dx2d
Alzheimer's Drug Discovery Foundation Invests $10M in Alamar Biosciences
The funding will be used to move the ARGO-HT research platform into an FDA-cleared system to support the development of diagnostic tests.
China Medical System （00867）Obtained New Drug ZUNVEYL for the Treatment of Mild-to-Moderate Dementia of the Alzheimer’s Type
As the second oral therapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of Alzheimer’s disease during the past decade, ZUNVEYL demonstrates a potentially better safety ...
China Medical System Secures Rights to Alzheimer’s Drug ZUNVEYL
Discover outperforming stocks and invest smarter with Top Smart Score StocksFilter, analyze, and streamline your ...
Johnson & Johnson Gets FDA Fast-Track Designation for Posdinemab in Alzheimer's
The New Brunswick, N.J., pharmaceutical giant said posdinemab has shown potential in targeting disease-associated phosphorylated tau in cerebrospinal fluid from treated Alzheimer's patients, and in ...
Alpha Cognition Inks $44 Million Licensing Pact For Its Alzheimer's Drug In China
Alpha Cognition and China Medical System sign a $44M licensing deal for Zunveyl. ALPHA-1062 preclinical data shows benefits ...
Why Alzheimer’s Scientists Are Re-thinking the Amyloid Hypothesis
For decades, scientists have been trying to develop therapeutics for people living with Alzheimer’s disease, a progressive ...
Annovis Bio says updated Alzheimer’s trial protocol accepted by FDA
Annovis Bio (ANVS) stock slipped after the company said the FDA accepted its updated protocol for a Phase 3 trial for its ...